Table 3

 Summary of recent studies investigating the sensitivity and specificity of canalicular immunostaining for CD10 and p-CEA

First authorCD10canp-CEAcan
HCC n/n (%)Non-HCC n/n (%)HCC n/n (%)Non-HCC n/n (%)
HCC, hepatocellular carcinoma; ND, not determined; p-CEA, antibody that crossreacts with biliary glycoprotein I.
Borscheri943/63 (68.3%)0/25 (0%)60/63 (95.2%)0/25 (0%)
Chu1150/96 (52.1%)ND73/96 (76.0%)ND
Lau1317/42 (40.5%)0/65 (0%)29/42 (69.0%)0/56 (0%)
Lee1521/75 (28.0%)0/399 (0%)NDND
Lin3519/22 (86.4%)0/23 (0%)NDND
Morrison1213/25 (52.0%)0/75 (0%)24/25 (96.0%)2/75 (2.7%)
Saad1023/30 (76.7%)0/30 (0%)24/30 (80.0%)0/30 (0%)
Xiao369/15 (60.0%)0/19 (0%)15/15 (100%)0/19 (0%)
Our present study33/53 (62.3%)0/33 (0%)43/53 (81.1%)0/33 (0%)
Summary228/421 (54.2%)0/669 (0%)268/324 (82.7%)2/238 (0.8%)